|
C10ORF18 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.38969996305627E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.00030000005358E-06 |
| Normal-vs-Stage2 |
2.366400E-04 |
| Normal-vs-Stage3 |
3.65499996934915E-09 |
| Normal-vs-Stage4 |
5.34499999815807E-10 |
| Stage1-vs-Stage2 |
9.219000E-01 |
| Stage1-vs-Stage3 |
5.804200E-02 |
| Stage1-vs-Stage4 |
5.722900E-03 |
| Stage2-vs-Stage3 |
1.542630E-01 |
| Stage2-vs-Stage4 |
5.207500E-02 |
| Stage3-vs-Stage4 |
4.671800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
4.50479999969389E-08 |
| Normal-vs-AfricanAmerican |
6.478800E-03 |
| Normal-vs-Asian |
2.50920000000043E-07 |
| Caucasian-vs-AfricanAmerican |
3.732800E-01 |
| Caucasian-vs-Asian |
4.517000E-01 |
| AfricanAmerican-vs-Asian |
1.628010E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.19030000025988E-07 |
| Normal-vs-Female |
1.78729999689153E-08 |
| Male-vs-Female |
7.662000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
5.68359999952861E-07 |
| Normal-vs-Age(41-60Yrs) |
2.11619999967994E-07 |
| Normal-vs-Age(61-80Yrs) |
1.40300000506244E-08 |
| Normal-vs-Age(81-100Yrs) |
3.160300E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.142200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.612640E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.915200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.154600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.222400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.982200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.559900E-03 |
| Classical-VS-Follicular |
9.169200E-01 |
| Classical-VS-Other |
4.713200E-01 |
| Classical-VS-Normal |
3.16029999947176E-08 |
| Tall-VS-Follicular |
3.907800E-02 |
| Tall-VS-Other |
6.624600E-01 |
| Tall-VS-Normal |
6.17990003615176E-09 |
| Follicular-VS-Other |
5.958400E-01 |
| Follicular-VS-Normal |
1.790350E-04 |
| Other-VS-Normal |
9.282300E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.61019999556089E-08 |
| Normal-vs-N1 |
1.9771000003832E-07 |
| N0-vs-N1 |
3.685600E-01 |
|
|
